anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sectral (acebutolol HCl) is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias. It is marketed in capsule form for oral administration. Sectral capsules are provided in two dosage strengths which contain 200 or 400 mg of acebutolol as the hydrochloride salt. The inactive ingredients present are D&C Red 22, FD&C Blue 1, FD&C Yellow 6, gelatin, povidone, starch, stearic acid, and titanium dioxide. The 200 mg dosage strength also contains D&C Red 28 and the 400 mg dosage strength also contains FD&C Red 40.

Acebutolol HCl has the following structural formula:  


Acebutolol HCl is a white or slightly off-white powder freely soluble in water, and less soluble in alcohol. Chemically it is defined as the hydrochloride salt of (±)N-[3-Acetyl-4-[2- hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl] butanamide.
The invention relates to the field of health products, and in particular relates to a health wine for removing chloasma and a traditional Chinese medicine composition contained in the health wine. The health wine for removing chloasma is prepared from the traditional Chinese medicine composition and a distilled spirit, wherein the traditional Chinese medicine composition comprises danshen root, Chinese angelica, rose, barbary wolfberry fruit, root of lobed kudzuvine and a grape seed extract. The invention also provides the traditional Chinese medicine composition and a preparation method thereof. Results of comparing different recipe composition groups show that the effects of a traditional Chinese medicine composition which is lack of danshen root, Chinese angelica, rose, barbary wolfberry fruit, root of lobed kudzuvine and the grape seed extract on inhibiting B-16 melanoma cell activity, tyrosinase activity and melanogenesis of mice are sequentially weakened, and whether danshen root and Chinese angelica are added or not can cause significant influences to the results. The results show that the traditional Chinese medicine composition and freckle-removing health wine provided by the invention have reasonable formulas, and each component is indispensable. After people drink the freckle-removing health wine provided by the invention, chloasma cannot be increased, and the effects of treating and preventing chloasma can also be played.
BACKGROUND: Tolerating physical tasks depends not only on task-specific characteristics but also on an individual's psychophysiological capacity to respond to the imposed load. People suffering from chronic low back pain (CLBP) may experience reduced psychophysiological capacity and are at risk for poor pain prognosis, which could lead to an increased walking workload.
AIM: To investigate how the risk of unfavorable pain prognosis in CLBP can impact walking physiomechanical parameters and psychophysiological workload.
METHODS: A cross-sectional observational study. The study classified 74 volunteers into four groups based on their prognosis for pain: pain-free control (CG/n = 20), low (LrG/n = 21), medium (MrG/n = 22), and high (HrG/n = 11) risk of poor prognosis for CLBP. The ground assessments identified the self-selected (SSW) and optimal (OWS) walking speeds, as well as the locomotor rehabilitation index (LRI). Treadmill assessments were conducted at two different speeds (0.83 and 1.11 m s-1, SSW and OWS) to record physiomechanical parameters. Psychophysiological workloads during walking were measured via workload impulse for the session (TRIMP), determined by variations in heart rate.
RESULTS: CLBP groups exhibited slower SSW and lower LRI compared to the CG. The TRIMP was lower in the LrG. However, both MrG and HrG exhibited a comparable overload to the CG, even while walking at a lower intensity with a psychophysical demand. SSW and OWS displayed an increased TRIMP compared to fixed speeds.
CONCLUSION: Psychosocial factors may affect SSW in people with CLBP but not among the risk strata. An unfavorable prognosis for pain could jeopardize the psychophysiological capacity to withstand walking demands.
A DNA sequence (-426 to +28 base pairs) cloned from the probasin (PB) gene promoter region confers androgen regulation in cell culture and prostate specific expression in transgenic non-human eukaryotic animals. Various PB promoter fragments impart preferential regulation by androgens compared to other steroid hormones on fused transgenes. Alteration of the DNA sequences and/or combinations of the sequences offer improvements on the sensitivity of the bioassay for androgenic and anti-androgenic materials where androgenic is defined as any ligand or pathway that leads to the activation of androgen action. This assay also measures the significance of alteration of amino acids in the androgen receptor on its bioactivity or ability to bind to DNA sequences. In transgenic non-human eukaryotic animals, the PB sequence directs fused transgene expression to the prostate which then can control the growth or function of prostatic cells. Expression of any gene specifically in prostatic cells or cells prostate in origin, can change the characteristics of those cells. Animal models for prostatic hyperplasia and prostate cancer can be developed as well as cells isolated from these new animal models can be placed into culture to develop new cell cultures models. Exposure of either animal or culture models to any material can determine effectiveness of therapies on prostatic disease for a cure or relief of symptoms. These same animal or culture models may test any material for carcinogenicity or protection against development of prostatic neoplasms. Further, the ability of PB to target trangenes to prostatic cells permits the targeting of genes to human prostatic cells for the treatment of human benign prostatic hyperplasia and human prostate cancer.
INTRODUCTION: Spine surgery is one of the most common types of surgeries performed in the United States; however, managing postoperative pain following spine surgery has proven to be challenging. Patients with spine pathologies have higher incidences of chronic pain and resultant opioid use and potential for tolerance. Implementing a multimodal plan for postoperative analgesia after spine surgery can lead to enhanced recovery and outcomes.
AREAS COVERED: This review presents several options for analgesia following spine surgery with an emphasis on multimodal techniques to best aid this specific patient population. In addition to traditional therapeutics, such as acetaminophen, non-steroidal anti-inflammatory medications, and opioids, we discuss intrathecal morphine administration and emerging regional anesthesia techniques.
EXPERT OPINION: Several adjuncts to improve analgesia following spine surgery are efficacious in the postoperative period. Intrathecal morphine provides sustained analgesia and can be instilled intraoperatively by the surgical team under direct visualization. Local anesthetics deposited under ultrasound guidance by an anesthesiologist trained in regional techniques also provide the opportunity for single injections or continuous analgesia via an indwelling catheter.
The present invention discloses a phagotrophy promoting factor, a coding sequence and application thereof. The present invention aims at providing the phagotrophy promoting factor, the coding gene thereof, and the application of the factor to the preparation of medicine for removing hemopathy pathogeny. The phagotrophy promoting factor is a protein with one of the following amino acid residue sequences: 1) SEQ ID No. 1 in a sequence table; 2) protein with the function of removing hemopathy pathogeny, wherein the protein with the function of removing hemopathy pathogeny is formed by substituting or deleting or adding one to ten amino acid residue in the amino acid residue sequence of the SEQ ID No. 1 in the sequence table. The phagotrophy promoting factor of the present invention performs the functions of directly killing pathogens and promoting white cells, red cells, etc., to adhere with phagocytizing and killing extraneous pathogeny, and performs other functions. The phagotrophy promoting factor sufficiently performs the function of rapidly removing pathogens in a broad spectrum mode. The phagotrophy promoting factor can be used as active ingredients for preparing medicine for removing hemopathy pathogeny, or can be combined with other kinds of medicine for preventing and treating the invasion of various hemopathy pathogens. The phagotrophy promoting factor has wide application prospect in the field of medicine.
Neurofibromatosis type 2 (NF2) is a hereditary tumor predisposition syndrome caused by mutations in the NF2 tumor suppressor gene. Individuals with NF2 have a higher likelihood to develop multiple nervous system tumors, including schwannomas, meningiomas, and ependymomas. The hallmark of NF2 is bilateral vestibular schwannomas. Historically, most NF2 patients experience complete hearing loss either from tumor progression or after treatment of the tumors with surgery or radiation. Effective treatments are urgently needed for NF2 patients with progressive hearing loss because hearing loss is associated with impairment in social, emotional,and communication function and with increased depression.

Previous studies of NF2 patients treated with bevacizumab suggested that inhibition of vascular endothelial growth factor (VEGF) could result in hearing improvement and reduction in tumor size.Recombinant human endostatin can inhibit the formation of blood vessels by inhibiting the migration of vascular endothelial cells .In this way, endostatin can inhibit the nutrition of the tumor and decrease the tumor's growth and metastasis. In vitro tests, endostatin can inhibit the cell migration and Tube formation of the microvascular endothelial cell line HHEC. Besides, it can inhibit blood vessels' formation of the chicken embryo sac membrane. Based on these studies, we perform this clinical trial to known the treatment effect and tolerability of endostatin on NF2.
Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patient's own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods of the invention may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing adipose derived endothelial cells are described. The cell delivery matrices maintain the adipose derived endothelial cells at the target for a therapeutically effective amount of time. The adipose derived endothelial cells can be allogenic or syngenic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents.
Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
AIMS: The purpose of the study was to build a radiomics model using Dual-energy CT (DECT) to predict pathological grading of invasive lung adenocarcinoma.
MATERIALS AND METHODS: The retrospective study enrolled 107 patients (80 low-grade and 27 high-grade) with invasive lung adenocarcinoma before surgery. Clinical features, radiographic characteristics, and quantitative parameters were measured. Virtual monoenergetic images at 50kev and 150kev were reconstructed for extracting DECT radiomics features. To select features for constructing models, Pearson's correlation analysis, intraclass correlation coefficients, and least absolute shrinkage and selection operator penalized logistic regression were performed. Four models, including the DECT radiomics model, the clinical-DECT model, the conventional CT radiomics model, and the mixed model, were established. Area under the curve (AUC) and decision curve analysis were used to measure the performance and the clinical value of the models.
RESULTS: The radiomics model based on DECT exhibited outstanding performance in predicting tumor differentiation, with an AUC of 0.997 and 0.743 in the training and testing sets, respectively. Incorporating tumor density, lobulation, and effective atomic number at AP, the clinical-DECT model showed a comparable performance with an AUC of 0.836 in both the training and testing sets. In comparison to the conventional CT radiomics model (AUC of 0.998 in the training and 0.529 in the testing set) and the mixed model (AUC of 0.988 in the training and 0.707 in the testing set), the DECT radiomics model demonstrated a greater AUC value and provided patients with a more significant net benefit in the testing set.
CONCLUSIONS: In contrast to the conventional CT radiomics model, the DECT radiomics model produced greater predictive performance in pathological grading of invasive lung adenocarcinoma.
1.Melphalan hydrochloride for injection must be reconstituted by rapidly injecting 10 mL of the supplied diluent directly into the vial of lyophilized powder using a sterile needle (20-gauge or larger needle diameter) and syringe. Immediately shake vial vigorously until a clear solution is obtained. This provides a 5 mg/mL solution of melphalan. Rapid addition of the diluent followed by immediate vigorous shaking is important for proper dissolution. 

2\. Immediately dilute the dose to be administered in 0.9% Sodium Chloride Injection, USP, to a concentration not greater than 0.45 mg/mL. 

3\. Administer the diluted product over a minimum of 15 minutes. 

4\. Complete administration within 60 minutes of reconstitution. 

The time between reconstitution/dilution and administration of melphalan hydrochloride for injection should be kept to a minimum because reconstituted and diluted solutions of melphalan hydrochloride for injection are unstable. Over as short a time as 30 minutes, a citrate derivative of melphalan has been detected in reconstituted material from the reaction of melphalan hydrochloride for injection with Sterile Diluent for melphalan hydrochloride for injection. Upon further dilution with saline, nearly 1% label strength of melphalan hydrolyzes every 10 minutes. A precipitate forms if the reconstituted solution is stored at 5°C. DO NOT REFRIGERATE THE RECONSTITUTED PRODUCT.
The safety and efficacy of conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant population have not been established [see Clinical Studies (14.4)]. In a study evaluating the safety and efficacy of conversion from calcineurin inhibitors to Rapamune (initial target sirolimus concentrations of 12–20 ng/mL, and then 8–20 ng/mL, by chromatographic assay) in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n = 87) with a baseline glomerular filtration rate of less than 40 mL/min. There was a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death, in this stratum of the Rapamune treatment arm.

The subset of patients with a baseline glomerular filtration rate of less than 40 mL/min had 2 years of follow-up after randomization. In this population, the rate of pneumonia was 25.9% (15/58) versus 13.8% (4/29), graft loss (excluding death with functioning graft loss) was 22.4% (13/58) versus 31.0% (9/29), and death was 15.5% (9/58) versus 3.4% (1/29) in the sirolimus conversion group and CNI continuation group, respectively.

In the subset of patients with a baseline glomerular filtration rate of greater than 40 mL/min, there was no benefit associated with conversion with regard to improvement in renal function and a greater incidence of proteinuria in the Rapamune conversion arm.

Overall in this study, a 5-fold increase in the reports of tuberculosis among sirolimus 2.0% (11/551) and comparator 0.4% (1/273) treatment groups was observed with 2:1 randomization scheme.

In a second study evaluating the safety and efficacy of conversion from tacrolimus to Rapamune 3 to 5 months post-kidney transplant, a higher rate of adverse events, discontinuations due to adverse events, acute rejection, and new onset diabetes mellitus was observed following conversion to Rapamune. There was also no benefit with respect to renal function and a greater incidence of proteinuria was observed after conversion to sirolimus [see Clinical Studies (14.4)].
The invention discloses an external traditional Chinese medicine composition for children defervescence, a gel plaster and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for children defervescence comprises radix bupleuri, cape jasmine and raw rhubarb. The preparation method of the external traditional Chinese medicine composition for children fever abatement comprises radix bupleuri aromatic water and extract. The gel plaster comprises bupleuri radix aromatic water, extract, sodium polyacrylate, aluminium glycollate, tartaric acid, polyvinylpyrrolidone, etc. The preparation method of the gel plaster comprises the steps of mixing, standing for swelling, mixing and stirring, and coating. The gel plaster prepared by the invention can simultaneously exert the efficacy of antipyresis of traditional Chinese medicine compatibility and the efficacy of physical cooling of the plaster; and the medicine has large medicine-carrying amount and convenient use, and provides a safe, effective and easily-accepted preparation for children with exogenous fever.
Employing various appropriate sensors, apparatus and software enable a mobile phone capable of motion detecting and physiological parameters detecting. Those sensors may built-in or external-connect. The external-connect sensors may connect with mobile phone via wire or via wireless. The obtained data can be integrated and applied by physiological theory for determining maximum oxygen uptake quantity and anaerobic threshold. The significance of those two index are extremely high in sports physiology and are possible to quantitatively evaluate the individual's endurance, set up a safe target zone for exercise and confirm the effects of training. Employing those data, index, which may expand the function of mobile phone to exercise measuring and workout support level. And by using the wireless data service function of mobile phone, real time monitoring and control during exercise will become available.
A method for preparing curcumin nano-drug, application and a method for constructing a three-dimensional tumor model are disclosed, wherein a polymer nonionic surfactant Pluronic F127 is compounded with curcumin to prepare the traditional Chinese medicine nano-particle CurNPs with good water solubility and good tumor treatment effect. The prepared gelatin/sodium alginate/nanoclay Gel/Alg/NC composite scaffold has good printing performance and biocompatibility. The therapeutic effect of CurNPs on metastatic breast cancer is researched by using a 3D tumor model constructed by using a scaffold-combined metastatic breast cancer (MDA-MB-231) cell. Compared with the 2D model, the Gel/Alg/NC cell model has better cell proliferation effect. In addition, there is a better EPR effect when CurNPs enter, and the accumulation at the 3D cell tumor site is better, representing a more real response to the tumor treatment effect of breast cancer cells. The combination of the nano material and the 3D cell tumor model provides a better alternative platform for drug screening, and has great potential for safe and effective breast cancer treatment screening.
A networked computer-based system, method, and computer program product for providing care to an infant is disclosed. First data is received through a first communication path at an event server from a first device. The first device may be a childcare device or the first device may be a user device, such as a user's cellular telephone, networked personal computing device, or a health/sleep monitor. The event server also receives second data from a second device through a second communication path. The first communication path and the second communication path being at least partially different. The second communication device may be childcare device. The event server determines whether to send a control signal to a controllable childcare device or send a control signal to controllable childcare device. The event server uses the first and second data and applies the data to predetermined logic to determine a result. A control signal is sent to the controllable childcare device for changing the state of the childcare device and causing it to assume a different behavior. In the alternative, an alarm message is sent to the personal computing device of a caregiver based upon the result.
PCT No. PCT/US96/18672 Sec. 371 Date Jun. 2, 1998 Sec. 102(e) Date Jun. 2, 1998 PCT Filed Nov. 22, 1996 PCT Pub. No. WO97/20540 PCT Pub. Date Jun. 12, 1997The present invention relates to cosmetic compositions in the form of a water-in-oil emulsion comprising: (a) discontinuous aqueous phase comprising an aqueous or hydroalcoholic solution of acidic skin care active; (b) continuous oil phase; and (c) pigment which has been coated with organosilicone component selected from a polyorganosiloxane and a silane, and mixtures thereof; characterized in that the aqueous phase has a pH of less than about 6 and the coated pigment has a hydrogen potential of less than about 2.0 ml H2/g of coated pigment. The compositions of the invention provide benefits in terms of reducing hydrogen gas generation and improving product stability.
Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
PURPOSE:To obtain the titled drug suitable as a medical preparation, by forming a thin membrane of lipid, adding calcium ion to the suspension of said membrane, freezing and thawing the mixture, and adding blood coagulation factor VIIIand a chelating agent to the product to form fat corpuscles. CONSTITUTION:Solvent is distilled off from a solution of a proper lipid to form a thin membrane of the lipid, which is suspended in a liquid, and added with calcium ion (final concentration of the ion is 10-30mM) to effect the coagulation of the membrane. The product is frozen, thawed, added with blood coagulation factor VIII (F-VIII) and then with a chelating agent (e.g. EDTA) to bond the calcium ion with chelate bond and to form fat corpuscles. Particles containing F-VIII and having diameter of about 0.01-1mu can be prepared by this process. Since the obtained F-VIII fat corpuscle preparation contains >=0.5 unit of F-VIII per 1mg of phospholipid, and has uniform and small particle diameter, it is useful as a remedy for hemophilia A, etc.